Prosecution Insights
Last updated: April 19, 2026
Application No. 17/989,103

SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS

Non-Final OA §102§103§112
Filed
Nov 17, 2022
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Enanta Pharmaceuticals Inc.
OA Round
5 (Non-Final)
68%
Grant Probability
Favorable
5-6
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
842 granted / 1237 resolved
+8.1% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
68 currently pending
Career history
1305
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.6%
-21.4% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is a Non-Final Office action. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 4, 2025 has been entered. Election/Restrictions Applicant’s election of Group (I) in the reply filed on September 29, 2023 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Group (I), drawn to compounds of formula (I) and compositions thereof, embraced by claims 1-10 was elected by Applicant. Applicant has not pointed to any errors in the Examiner’s analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected the following species: PNG media_image1.png 129 234 media_image1.png Greyscale , and indicated claims 1-7, 9 and 10 read on said species. The elected species was not found, and thus, the search was expanded. Claims 1-17 are pending and claims 1-7, 9 and 10 are under examination. Claim 8 is withdrawn based on the species election. Claims 11-17 are withdrawn based on the restriction requirement. Priority Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) (PROVISIONAL) or 119(a) (FOREIGN) or under 35 U.S.C. 120 (CONT/CIP), 121(DIV), or 365(c) (WO) is acknowledged. Applicant still has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent application (the parent for an invention which is also disclosed in the prior application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63280933, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for claim 9 of this application. There may be other omissions as well. Thus, the effective filing date of the present claim 9 remains the immediate filing date of November 17, 2022. Claim Objections Claims 4-7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. With regards to claim 3, the phrase “R1 is derived from” is vague. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The rejection of claims 1, 2, 4-6 and 10 under 35 U.S.C. 102(a)(1) being anticipated by Pellegrini et al. (Tetrahedron Asymmetry, 1994, 5(10), 1979-1992) is withdrawn based on the amendments. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 2 and 10 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Wang et al. (US 20230103494). The reference teaches the following species: PNG media_image2.png 308 418 media_image2.png Greyscale PNG media_image3.png 307 380 media_image3.png Greyscale PNG media_image4.png 272 368 media_image4.png Greyscale PNG media_image5.png 275 384 media_image5.png Greyscale and PNG media_image6.png 325 403 media_image6.png Greyscale , among others. All the compounds in the specification have the (R) configuration at the spiro carbon and the (S) configuration at X. Therefore, said claims are anticipated by Wang et al. The applied reference has common inventors with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Claims 1, 2 and 10 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Wang et al. (US 20220162231). The reference teaches the following species: PNG media_image7.png 112 897 media_image7.png Greyscale PNG media_image8.png 254 361 media_image8.png Greyscale . All the compounds in the specification have the (R) configuration at the spiro carbon and the (S) configuration at X. Therefore, said claims are anticipated by Wang et al. The applied reference has common inventors with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claim 9 is rejected under AIA 35 U.S.C. 103(a) as being unpatentable over Luo et al. (WO 2023109926). The present application claims the following species: PNG media_image9.png 89 322 media_image9.png Greyscale , see claim 9, page 13. The reference teaches the following species: PNG media_image10.png 329 865 media_image10.png Greyscale PNG media_image11.png 144 132 media_image11.png Greyscale , see page 21. All the compounds in the specification have the (R) configuration at the spiro carbon and the (S) configuration at the CN bond. The only difference is the substitution at R1, t-butyl alkyl group versus Applicant’s ethyl or isopropyl alkyl group. Since a t-butyl group is considered a homolog of ethyl and isopropyl groups these compounds are considered equivalent. The MPEP 2144.09 states “Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Therefore, said claims are obvious over Luo et al. Applicant removed species 67 but species 68 is still pending in the claims. Therefore, the rejection is maintained over species 68. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached on Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Nov 17, 2022
Application Filed
Jan 23, 2024
Non-Final Rejection — §102, §103, §112
Apr 16, 2024
Response Filed
Jul 11, 2024
Final Rejection — §102, §103, §112
Sep 17, 2024
Response after Non-Final Action
Oct 16, 2024
Request for Continued Examination
Oct 18, 2024
Response after Non-Final Action
Feb 15, 2025
Non-Final Rejection — §102, §103, §112
May 13, 2025
Response Filed
Jun 09, 2025
Final Rejection — §102, §103, §112
Sep 24, 2025
Response after Non-Final Action
Nov 04, 2025
Request for Continued Examination
Nov 06, 2025
Response after Non-Final Action
Feb 15, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600717
TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
2y 5m to grant Granted Apr 14, 2026
Patent 12583868
JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570656
PURINE COMPOUNDS FOR TREATING DISORDERS
2y 5m to grant Granted Mar 10, 2026
Patent 12552810
CRYSTALLINE FORMS OF CFTR MODULATORS
2y 5m to grant Granted Feb 17, 2026
Patent 12552804
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+32.2%)
3y 0m
Median Time to Grant
High
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month